Logo image of ALT

ALTIMMUNE INC (ALT) Stock Fundamental Analysis

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

6.43  -0.2 (-3.02%)

After market: 6.43 0 (0%)

Fundamental Rating

3

Overall ALT gets a fundamental rating of 3 out of 10. We evaluated ALT against 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ALT as it has an excellent financial health rating, but there are worries on the profitability. ALT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALT had negative earnings in the past year.
In the past year ALT has reported a negative cash flow from operations.
In the past 5 years ALT always reported negative net income.
ALT had a negative operating cash flow in each of the past 5 years.
ALT Yearly Net Income VS EBIT VS OCF VS FCFALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

ALT has a Return On Assets of -70.01%. This is in the lower half of the industry: ALT underperforms 65.72% of its industry peers.
ALT has a Return On Equity of -77.61%. This is comparable to the rest of the industry: ALT outperforms 52.93% of its industry peers.
Industry RankSector Rank
ROA -70.01%
ROE -77.61%
ROIC N/A
ROA(3y)-42.43%
ROA(5y)-37.21%
ROE(3y)-46.68%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
ALT Yearly ROA, ROE, ROICALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALT Yearly Profit, Operating, Gross MarginsALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50K 100K

More info and screens

8

2. Health

2.1 Basic Checks

ALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALT has been increased compared to 1 year ago.
The number of shares outstanding for ALT has been increased compared to 5 years ago.
There is no outstanding debt for ALT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALT Yearly Shares OutstandingALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALT Yearly Total Debt VS Total AssetsALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

ALT has an Altman-Z score of 13.33. This indicates that ALT is financially healthy and has little risk of bankruptcy at the moment.
ALT has a better Altman-Z score (13.33) than 88.99% of its industry peers.
ALT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.33
ROIC/WACCN/A
WACC9.44%
ALT Yearly LT Debt VS Equity VS FCFALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 16.87 indicates that ALT has no problem at all paying its short term obligations.
ALT's Current ratio of 16.87 is amongst the best of the industry. ALT outperforms 90.59% of its industry peers.
ALT has a Quick Ratio of 16.87. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 16.87, ALT belongs to the best of the industry, outperforming 90.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.87
Quick Ratio 16.87
ALT Yearly Current Assets VS Current LiabilitesALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ALT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.99%, which is quite good.
ALT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -81.43%.
ALT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -47.15% yearly.
EPS 1Y (TTM)12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.95%
Revenue 1Y (TTM)-81.43%
Revenue growth 3Y-62.67%
Revenue growth 5Y-47.15%
Sales Q2Q%-98.62%

3.2 Future

The Earnings Per Share is expected to grow by 33.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALT will show a very strong growth in Revenue. The Revenue will grow by 282.13% on average per year.
EPS Next Y5.76%
EPS Next 2Y-1.48%
EPS Next 3Y-5.92%
EPS Next 5Y33.23%
Revenue Next Year-98.05%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y282.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALT Yearly Revenue VS EstimatesALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 500M 1B 1.5B
ALT Yearly EPS VS EstimatesALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALT. In the last year negative earnings were reported.
Also next year ALT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALT Price Earnings VS Forward Price EarningsALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALT Per share dataALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

ALT's earnings are expected to decrease with -5.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.48%
EPS Next 3Y-5.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTIMMUNE INC

NASDAQ:ALT (2/21/2025, 8:00:56 PM)

After market: 6.43 0 (0%)

6.43

-0.2 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-25 2025-03-25/amc
Inst Owners60.57%
Inst Owner Change2.32%
Ins Owners0.75%
Ins Owner Change2.68%
Market Cap457.30M
Analysts81.67
Price Target22.15 (244.48%)
Short Float %33.11%
Short Ratio8.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.42%
Min EPS beat(2)-1.62%
Max EPS beat(2)10.46%
EPS beat(4)3
Avg EPS beat(4)10.45%
Min EPS beat(4)-1.62%
Max EPS beat(4)24.64%
EPS beat(8)7
Avg EPS beat(8)14.39%
EPS beat(12)11
Avg EPS beat(12)14.33%
EPS beat(16)13
Avg EPS beat(16)9.29%
Revenue beat(2)2
Avg Revenue beat(2)546.85%
Min Revenue beat(2)496.45%
Max Revenue beat(2)597.25%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.39%
PT rev (3m)5.56%
EPS NQ rev (1m)4.26%
EPS NQ rev (3m)22.29%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.3%
Revenue NY rev (3m)11.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8794.26
P/FCF N/A
P/OCF N/A
P/B 3.43
P/tB 3.43
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS1.88
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -70.01%
ROE -77.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.43%
ROA(5y)-37.21%
ROE(3y)-46.68%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.87
Quick Ratio 16.87
Altman-Z 13.33
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)158.63%
Cap/Sales(5y)96.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.95%
EPS Next Y5.76%
EPS Next 2Y-1.48%
EPS Next 3Y-5.92%
EPS Next 5Y33.23%
Revenue 1Y (TTM)-81.43%
Revenue growth 3Y-62.67%
Revenue growth 5Y-47.15%
Sales Q2Q%-98.62%
Revenue Next Year-98.05%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y282.13%
EBIT growth 1Y-16.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.43%
EBIT Next 3Y-18.41%
EBIT Next 5Y-7.38%
FCF growth 1Y-15.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.15%
OCF growth 3YN/A
OCF growth 5YN/A